

Chloramphenicol Toxicity: A Review

Pooja Shukla, *F. W. Bansode and R. K. Singh**

Divisions of Toxicology and *Endocrinology,
CSIR – Central drug Research Institute,
Lucknow- 226001
INDIA

** Corresponding author: Mailing address: Division of Toxicology, CSIR – Central Drug Research Institute, Lucknow, India – 226001. Phone:919984941595. E – mail: rktox@yahoo.com

Abstract

Chloramphenicol (CAP) is a potent and efficient antibiotic used since years against many pathogens. Despite being highly effective, it shows severe toxicity in the form of Aplastic anemia (AA) and bone marrow suppression. Its D – form is the toxic one and inhibits protein synthesis. In living system, CAP is hydrolyzed and absorbed completely. Its excretion is also at a high rate but is highly impaired in disorders associate liver and kidneys. It is metabolized in liver to Chloramphenicol glucuronide. Being highly toxic, it is still prescribed at a noticeable rate. It is recommended to be prescribed to be only when there is no other alternative is present with a monitoring of its concentration in patients body. Chloramphenicol induced hematotoxicity was demonstrated in rats which recovered due to oral administration of coconut water within two weeks.

Keyword: Chloramphenicol; Toxicity; antibiotic; Aplastic anemia; hematotoxicity

Introduction

Chloramphenicol (CAP) is a broad spectrum antibiotic, was first quarantined from bacterium *Streptomyce venezualae* in the year 1947. It was available by the trade name of Chloromycetin by Parke Davis & Co. It was prescribed in mass in 1948 in USA following g an outburst of enteric fever. In 1949 it was available by the trade name of Chloromycetin by Parke Davis & Co. It was prescribed in mass in 1948 in USA following an outburst of enteric fever. In 1949 it was cleared from Federal Food and Drug, since then it has been used and worked upon extensively. Being a potent inhibitor of protein synthesis (Cundliffe, E.,McQuillen, K., 1967). It is extremely useful and active against a variety of pathogens including bacteria, *Spirochaetes*, *Rickettsiae* (Harrel, G. T., 1952;Smadel, J. E., Jackson, E. B., 1947 (a);Smadel, J. E., et al., 1949 (b);McClellan,J.W.,*et al.*, 1949),*Chlamydiae* (Harrel, G.T., 1952), Mycoplasmas (Denny, F.W., *et al.* 1971), *Tryponemapallidum* (Smadel, J. E. *et al.* 1949 (b); Romansky, M. J.,*etal.*,1949), *Borrelia*(McClellan, J. W.,*et al.*, 1949), *Leptospira* (Romansky, M. J.,*et al.*,1949), *Pseudomonas pseudomallei* (Howe, C., *et al.*, 1971) and *Actinomyces* (McClellan, I. W. ,*et al.*, 1949). It has bacterial action against *Haemophilus influenza* (Wehrle, P. F., *et al.*, 1967; Overturf, G. P. *et al.*, 1975; Rahal, J. J., Jr., Simberkoff, M. S., 1979),*Streptococcus pneumonia* (Wehrle, P. F., *et al.*, 1967; Rahal, J. J., 1979) and *Neisseria meningitidis* (Wehrle, P. F., *et al.*, 1967; Rahal, J. J., 1979). It shows no activity against parasites, fungi, mycobacteria and *Pseudomonas aeruginosa*.

Chemistry:

Chemically chloramphenicol is D-(-)-threo-1-p-nitrophenyl-2-dichloroacetamido 1,3-propanediol. It is in the form of a white, crystalline, neutral compound that is completely soluble in alcohol and is water insoluble. Chemically, it has two chiral centers leading to its four stereoisomers which include D – erythro and L – erythro isomers. Out of these, D – erythro has 98% bacteriostatic potency, whereas, L – erythro has only 2%. This is because of the fact that proteins have L – amino acids and D – erythro isomers fits in it due to its geometry and thus acts as protein synthesis inhibitor. CAP is available in two esterified forms; Palmitate and Succinate, both are ineffective against microbes (Glazko, A. J., *et al.*, 1952 (b); Ross, S., *et al.* 1952). CAP is tasteless in suspension whereas, CAP Succinate is water soluble ester suitable for *ivuse*.

Pharmacology:

Route of administration has no effect on CAP metabolism in the biological system. Esters of CAP has different hydrolysis patterns which is very rapid (Glazko, A. J., *et al.*, 1952 (b); Ross, S., *et al.* 1952). In a study, 8 cats were provided the ocular application of 1% CAP ointment at 8 hour interval for 21 days, at the dose levels of 2.7 mg/cat/day. On 21st day plasma concentrations were measured to be .09 µg/ml (Conner, G. H., Gupta, B.N., 1973). CAP succinate is hydrolysed by liver, lungs and kidneys (Pickering, L. K., *et al.*, 1980). CAP palmitate is hydrolysed to CAP prior to gastrointestinal absorption. Crystalline CAP is resorbed rapidly and almost completely from gastrointestinal tract (Glazko, A. J., *et al.*, 1952 (b)). CAP is metabolized primarily in liver to CAP glucuronide which has no known toxicity (Glazko, A. J., *et al.*, 1949 (a)).

Absorption of CAP is complete (Sutherland, J. M., 1959; Glazko, A. J., *et al.*, 1968 (c)) with a total body clearance of 0.122 – 0.429 liters/kg/hr (Sack, C. H., *et al.*, 1980). HPLC analysis revealed that the biotransformation of CAP takes place by oxidation, reduction and conjugation (Holt, D. E., 1995). CAP Succinate is converted into CAP, nitro – CAP and other metabolites after 1 hour and 15 minutes of administration (Ambekar, C. S., *et al.*, 2000).

Most of the CAP is completely metabolized, remaining 5 – 10% is excreted unchanged in urine by glomerular filtration (Glazko, A. J., *et al.*, 1949 (a); Ley, H. L., *et al.*, 1948) and 0.14% in bile (Glazko, A.J., *et al.*, 1949 (a)). Similar to other antibiotics, CAP is also eliminated by kidneys (Lindberg, A. A., *et al.*, 1966). Maximum concentration and speed of elimination are proportional to dose administered (Glazko, A. J., *et al.*, 1952 (b)).

Half-life:

Half Life of CAP varies with age and clinical manifestations. In normal adults, CAP has a half-life of 1.6 – 3.3 hours (Kunin, C. M., *et al.*, 1959) whereas in neonates it is 0.87 – 17.8 hours (Friedman, C. A., *et al.*, 1979). In anuric adults half-life increases upto the 3.2 - 4.2 hours (Kunin, C. M., *et al.*, 1959) with an accumulation of CAP glucuronide.

In cases of liver disorders (totally or partially impaired liver functions) CAP metabolism is highly impaired (Azzollini, F., *et al.*, 1972; Koup, J. R., *et al.*, 1979 (b)) and half-life may increase up to 3 – 12 hours (Kunin, C. M., *et al.*, 1959). In neonates, serum levels reach very high up to 313 µg/ml (Suazer, C. R., *et al.*, 1992). Renal impairment has no effect on the elimination rate of active and potentially toxicity free drug (Goodman and Gillman, 1992).

CAP in food and food industry:

Some studies suggest the use of CAP in food. Although, most countries have banned CAP from animal food production, still traces of it have been detected in shrimp and other aquaculture products. According to regulations promulgated in 1980's and 1990's, use of CAP in food was banned and countries have established a zero tolerance policy. In Japan, zero tolerance threshold for CAP is 50 ppb which in USA is 5 ppb. Meat and offal from treated animals contained CAP and its non – genotoxic metabolites (Milhaud, G., 1993).

Interaction with other drugs:

In general, CAP inhibits metabolism of other drugs such as tolbutamide ,diphenylhydantoin, dicumarol and penicillin (Christensen, L. K.;Saovstev, L., 1969; Koup , J. R. , *et al.*,1978 (a); Jatwetz, E., *et al.*, 1951), phenobarbital and paracetamol being an exception. Use of CAP and phenobarbital results in unexpectedly high levels of phenobarbital in serum (Koup, J. R. , *et al.*, 1978 (a)). Paracetamol has no effect on CAP metabolism (Paap, C.H., Nahata, H. C., 1990) with no change in its half-life and plasma concentration (Stein *et al.*, 1989).

CAP and Aplastic anaemia :

Even being a potent antibiotic with a broad range of spectrum, the use of CAP is limited due to its association with aplastic anaemia (AA) (Rich, M. L.,*et al.*, 1950) and bone marrow suppression (Amberkar, C. E., *et al.*, 2000). AA is a rare, dose independent , irreversible, idiosyncratic, manifestation of CAP which in most cases is seen years after the treatment (Younis, A.A. ,1989 (b)) and is fatal (Turton, A. A., 2002) risk of developing AA after CAP administration is 1:30000 to 1:5000015 (Li,C.H, *et al.*, 2010).

CAP associated AA cannot be predicted by the monitoring of blood cell counts. Percent mortality is around ~50% and in neonates it is ~ 40 % (Suazer C. R., Ow,E. T., 1992). Prognosis is poor, if AA develops after a long time of treatment (Polak, B. C. P.,*et al*, 1972). Studies suggest the higher occurrence of AA in black patients (Best, W. R.,1967; Wallerstein,R.O., *et al*,1969). Only orally administered CAP leads to AA (Holt, R., 1967; Gleekman, R. A., 1975) This has made the CAP to be prescribed parenterally by many physicians. It is not known whether this lowers the incidence of AA or not but yes the risk is obviously lowered. Other than oral and parenterally absorbed CAP, it is also used as ophthalmic preparations where AA is also very rare (Rosenthal, R. L.,Blackman, A., 1965; Carpenter, G., 1975; Abrams, S. M.,*et al.*, 1980)

Mechanisms Involved in CAP induced AA:

Earlier, AA was hypothesized to occur due to genetic metabolic defect or the manifestation was theorized because of the genetic predisposition of the being. The theory states CAP induce and enhances these defects which results in damage to undifferentiated marrow stem cells (Cronkite, E. P., 1964)

A different theory suggests that certain enteric bacteria can produce a specific enzyme that degrades CAP to a toxic product (Holt, R., 1967). This was suggested by further studies, which suggests that the metabolites of CAP generated by intestinal bacteria undergo further metabolic

transformations in system with *in situ* production of toxic intermediate (Yunis, A. A., 1989 (b))
Rarity of these enzyme producing enteric bacteria explain the infrequency of AA.

In a study (Yunis, A. A, 1973 (a)) it was actually revealed that the p-nitrosulfathiazole group is responsible for AA by inhibiting DNA synthesis in marrow stem cells. This theory was based on the observation that thiamphenicol which is a CAP derivative, does not have a p-nitrosulfathiazole group and does not cause AA and thus, extensively used in Europe. This theory was further supported by studies indicating CAP reduced to p-nitrosulfathiazole which is a short lived reduction intermediate and leads to helix destabilization and strand breakage(Irena, M. S., *et al.*, 1983) except than being unstable. These intermediates are highly toxic (Eyer, P., *et al.*, 1984)

At a concentration of 2000-4000 µg/ml CAP depressed phagocytosis and burst activity of neutrophils (Paape, M. J.,*et al.*,1990). Other studies suggests that CAP directly induce apoptosis in haematopoietic stem cells, directly leading to AA (Kong C. T., *et al.*, 2000).

In a study, Chloramphenicol was administered at dose levels of 150 mg/kg in rats for 14 days which caused significant haematotoxicity characterized by decrease in RBC count, Hb% and WBC count which were indicators of anemia. (Dubey, Chetan, *et al.*, 2011)

Clinical Usage and Prescriptions:

In 1952 (3 years after giving the “safe to use” certification to CAP) FDA conducted a survey on the association of CAP to AA. This resulted in the finding that the 68% of the population with prolonged therapy to CAP has one or the other type of blood dyscrasia(Lewis, C. N.,*et al.*, 1952). Afterwards, labels were required with the warning that blood dyscrasia may be associated with the intermittent or prolonged use of CAP. Practitioners were instructed not to prescribe it intermittently. It is to be used for a very few serious and potentially fatal infections against which no safer alternative is present. As in earlier, this drug had been prescribed for inappropriate or trivial infections such as common cold, bronchitis, tonsillitis and acne, (Best, W. R.,1967). In neonates it was prescribed at doses higher than those recommended for older subjects (Weiss, C. F., *et al.*, 1960)

After the warning signal being presented there is a noticeable decrease in AA cases. CAP is still prescribed especially in the treatment of *H. influenza* which is ampicillin resistant (McGowan, J. E., *et al.*, 1976). It is also used to treat infections caused by Vancomycin resistant enterococci that are resistant to other antibiotic regimes. It is also a drug of choice in penicillin resistant meningitis caused by *H. influenzae*, *S.pneumoniae* and *N. meningitides* (Westenfelder, G.O., *et al.*, 1969). CAP is still being used in endemic areas (at dose levels higher than the permissible ones) which is suggested by the decline in resistance to multi drugs by the strains of *S.typhi*, (Thaver, D., *et al.*, 2009). CAP is being used in developing countries for patients of all age groups (Weber, H. W. *et al.*, 1999)

Fluoroquinolones have come up as an safe and efficient first line antibiotic alternative but significant differences in clinical manifestations usually occur (Thaver, D.,*et al.*, 2009)

Use of CAP is controversial especially in the light of such a long list of alternative antibiotics. For the patients, still sticking to CAP prescription, it is recommended to keep a routine check of

Hgb, WBC, RBC, platelet and Reticulocyte count. Even a slight increase in plasma concentration should lead to immediate stoppage of drug continuation.

Acknowledgement

CDRI Communication No. 8195

References:

1. Abrams, S. M., Degnan, T. J., Vinciguerra, V. Marrow aplasia following topical application of chloramphenicol eye ointment. *Arch. Intern. Med.* 140:576 – 577, 1980.
2. Ambeker, C. E., Cheung, B., Lee, J., Chan, L. C., Liang, R., Kumana, C. R. Metabolism of chloramphenicol succinate in human bone marrow. *Eur. J. Clin. Pharmacol.* 56:405 – 409, 2000.
3. Azzollini, F., Gazzaniga, A., Lodola, E., Natangelo, R. Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. *Int. J. Clin. Pharmacol.* 6:130 – 134, 1972.
4. Best, W. R., Chloramphenicol – associated blood dyscrasias – A review of cases submitted to the American medical association registry. *J. A. M. A.* 201:181 – 188, 1967.
5. Carpenter, G., Chloramphenicol eye drops and marrow aplasia [letter]. *Lancet* 2:326 – 327, 1975.
6. Christensen, L. K., Skovsted, I. Inhibition of drug metabolism by chloramphenicol. *Lancet* 2:1397 – 1399, 1969.
7. Conner, G. H., Gupta B. N. Bone marrow, blood and assay levels following medication of cats with chloramphenicol ophthalmic ointment. *Vet. Med. SAC*, 885 – 899, 1973.
8. Cronkite, E. P. Enigmas underlying study of haemopoietic cell proliferation. *Fad. Proc.* 23:649 – 661, 1964.
9. Cundliffe, E., McQuillen, K., Bacterial protein synthesis: the effects of antibiotics. *J. Mol. Biol.* 30:137 – 146, 1967.
10. Denny, F. W., Clyde, W. A., Jr., Glezen, W. P. Mycoplasma pneumonia disease: clinical spectrum, patho – physiology, epidemiology and control. *J. Infect. Dis.* 123:74 – 92, 1971.
11. Dubey Chetan, Saxena Abhilasha, Gupta Rakhi, Singh Poonam, Bansode F.W. and Singh R.K. Assessment of Toxic Effects of Chloramphenicol in Rats and It's Amelioration by Coconut water. *Res. J. Chem. & Environ.* Accepted, Dec. 2011.
12. Eyer, P., Lierheimer, E., Schneller, M., Reactions of nitrosochloramphenicol in blood. *Biochem. Pharmacol* 33:2299 – 2308, 1984.
13. Friedman, C. A., Lovejoy, F. C., Smith, A. L. Chloramphenicol disposition in infants and children. *J. Pediatr.* 95:1071 – 1077, 1979.

14. Glazko, A. J., Wolf, L. M., Dill, W. A., Bratton, A. C., Jr. biochemical studies on chloramphenicol (chloromycetin). *J. Pharmacol. Exp. Ther.* 96:445 – 459, 1949.(a)
15. Glazko, A. J., Edgerton, W. H., Dill, W. A., Lenz, W. R. Chloromycetinpalmitate – a synthetic ester of chloromycetin. *Antibiot. Chemother.* 2:234 – 242, 1952.(b)
16. Glazko, A. J., Kinkel, A. W., Alegnani, W. C., Holmes, E. L. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. *Clin. Pharmacol. Ther.* 9:472 – 483, 1968.(c)
17. Gleckman, R.A. Warning-chloramphenicol may be good for your health. *Arch. Intern. Med.* 135:1125 – 1126, 1975.
18. Goodman and Gilman, the pharmacological basics of therapeutics. 8th Edition. Pergamon Press, New York, 1125 – 1130, 1992.
19. Harrel, G. T., Treatment of Rocky Mountain spotted fever with antibiotics. *Ann. N. Y. Acad. Sci.* 55:1027 – 1042, 1952.
20. Holt, D. E., Hurley, R., Harvey, D., A reappraisal of chloramphenicol metabolism: Detection and quantification of metabolites in the sera of children. *J. Antimicrobe. Chemother.* 35:115 – 127, 1995.
21. Holt, R. The bacterial degradation of chloramphenicol. *Lancet* 1:1259-1260, 1967.
22. Howe, C., Sampat, A., Spotnitz, M. The pseudomallei group: A review. *J. Infect. Dis.* 124:598 – 606, 1971.
23. Irena, M., Skolimowski, Knight, R.C., Edwards, D. I., Molecular basis of chloramphenicol and thiamphenicol toxicity to DNA *in vitro*. *J. Antimicrob. Chemother.* 12(6):534 – 542, 1983.
24. Jawetz, E., Gunnisol, J. B., Speck, R.S., Coleman, V. R. Studies on antibiotic synergism and antagonism: The interference of chloramphenicol with the action of penicillin. *Arch. Intern. Med.* 87:349 – 359, 1951.
25. Kong, C. I., Holt, D. E., Ma, S. K., Lie, A. K., Chan, L. C., Effects of antioxidants and a caspase inhibitor on chloramphenicol induced toxicity on human bone marrow and HL 60 cells. *Hum. Exp. Toxicol.* 19(9):503 – 510, 2000.
26. Koup, J. R., Gibaldi, M., McNamara, P., Hilligoss, D. M., Colburn, W. A., Bruck, E. Interaction of chloramphenicol with phenytoin and phenobarbital. *Clin. Pharmacol. Ther.* 24:571 – 575, 1978.(a)
27. Koup, J. R., Lau, A. H., Brodsky, B., Slaughter, R. L. Chloramphenicol pharmacokinetics in hospitalized patients. *Antimicrob. Agents Chemother.* 15:651 – 657, 1979.(b)
28. Kunin, C. M., Glazko, A. J., Finland, M. Persistence of antibiotics in blood of patients with severe renal diseases or hepatic cirrhosis. *J. Clin. Invest.* 38:1498 – 1509, 1959.

29. Lewis, C. N., Putnam, I. E., Hendricks, F. D., Kerlan, I., Welch, H. Chloramphenicol (Chloromycetin) in relation to blood dyscrasias with the observations on other drugs. *Antibiot. Chemother.* 2:601 – 609, 1952.
30. Ley, H. L., Jr., Smadel, J. E., Crocker, T. T. Administration of Chloromycetin to normal human subjects. *Proc. Soc. Exp. Biol. Med.* 68:9 – 12, 1948.
31. Li, C. H., Cheng, Y. W., Liao, P. L., Chloramphenicol causes mitochondrial stress , decreases ATP biosynthesis, induces matrix metalloproteinase – 13 expression, and solid tumor cell invasion. *Toxicol Sci.* 116(1): 140 – 150, 2010.
32. Lindberg, A. A., Nilsson, L. H., Bucht, H., Kallings, L. O., Concentration of chloramphenicol in the urine and blood in relation to renal function. *Brit. Med. J.* 2:724 – 728, 1966.
33. McGowan, J. E., Jr. Terry, P. M., Nahmias, A. J. Susceptibility of *Haemophilus influenzae* isolates from blood and cerebrospinal fluid to ampicillin, chloramphenicol and trimethoprim – Sulphamethoxazole. *Anti – microbe. Agents Chemother.* 9:137 – 139, 1976.
34. McLean, I. W. Jr., Schwab, J. L., Hillegas, A. B., Schlingman, A. S. Susceptibility of microorganisms to chloramphenicol(chloromycetin). *J. Clin. Invest.* 28:953 – 963, 1949.
35. Milhaud, G., Metabolic study discussion on chloramphenicol WHO report, 1983.
36. Overturf, G. D., Wilkins, J., Leedom, J. M., Ivler, D., Mathies, A. W. Susceptibility of *Haemophilus influenzae* type b, to ampicillin at Los Angeles county/ University of southern California medical center. *J. Pediatr.* 87:297 – 300, 1975.
37. Paap, C. M., Nahatha, H. C., Clinical pharmacokinetics of antibacterial drugs in neonates. *Clin. Pharmacokinet.*, 19:280 – 318, 1990.
38. Paape, M. J., Nickerson, S. C., Ziv. G. *In vivo* effects of chloramphenicol, tetracycline, and gentamicin on bovine neutrophil function and morphologic features. *Am. J. Vet. Res.* 51:1055 – 1061, 1990.
39. Pickering, L. K., Hoecker, J. L., Kramer, W. G., Kohl, S., Clearly, T. G. Clinical pharmacology of two chloramphenicol preparations in children: sodium succinate (iv) and palmitate (oral) esters. *J. Pediatr.* 96:757 – 761, 1980.
40. Polak, B. C. P., Wesseling, H., Schut, D., Herxheimer, A., Meyler, L. Blood dyscrasias attributed to chloramphenicol. *Acta. Med. Scand.* 192:409 – 414, 1972.
41. Rahal, J. J. Jr., Simberkoff, M. S. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens. *Antimicrob. Agents Chemother.* 16:13 – 18, 1979.
42. Rich, M. L., Ritterhoff, R. J., Hoffman, R. J. A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy. *Ann. Inter. Med.* 33: 1459 – 1467, 1950.

43. Romansky, M. J., Olansky, S., Taggart, S. R., Robin, E. D. The antitreponemal effects of oral chloromycetin in 32 cases of early syphilis in man – A preliminary report. *Science* 110:639 – 640, 1949.
44. Rosenthal, R. L., Blackman, A. Bone marrow hypoplasia following use of chloramphenicol eyedrops. *J. A. M. A.* 191:136 – 173, 1965.
45. Ross, S., Burke, F.G., Rice, E. C. The use of chloromycetinpalmitate in infants and children : a preliminary report. *Antibiot. Chemother.* 2:199 – 207, 1952.
46. Sack, C. M., Koup, J. R., Smith, A. L. Chloramphenicol pharmacokinetics in infants and young children. *Pediatr.* 4:579 – 584, 1980.
47. Smadel, J. E., Jackson, E. B., Chloromycetin, an antibiotic with chemotherapeutic activity in experimental rickettsial and viral infections. *Science* 106:418 – 419, 1947.(a)
48. Smadel, J. E., Bailey, C. A., Mankikar, D. S., Preliminary report on the use of chloramphenicol (chloromycetin) in the treatment of acute gonorrhoeal urethritis. *J. Clin. Invest.* 28:964 – 967, 1949.(b)
49. Stein, C. M., Thronhill, D. P., Neill, P., Nyazema, N. Z., Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol. *Br. J. Clin. Pharmacol.*, 27:262 – 264, 1989.
50. Suazer, C. R., Ow, E. P. Chloramphenicol toxicity associated with severe cardiac dysfunction. *Pediatr. Cardiol.* 13(1):48 – 51, 1992.
51. Sutherland, J. M. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. *Am. J. Dis. Child.* 97:761 – 767, 1959.
52. Thaver, D., Zaidi, A. K. M., Critchley, J., Azmatullah, A., Madni, S. A., Zulfigar, A. B. A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis. *B. M. J.* 338:b1865, 2009.
53. Turton, A. A., Andrews, C. M., Harvard, A. C., Williams, T. C., Studies on haematotoxicity of chloramphenicol succinate in Dunkin Hartley guinea pig. *Int. J. Exp. Pathol.* 5:225 -238, 2002.
54. Wallerstein, R. O., Condit, P. K., Casper, C. K., Brown, J. W., Morrison, F. R. State wide study of chloramphenicol therapy and fatal aplastic anaemia. *J. A. M. A.* 208:2045 – 2050, 1969.
55. Wehrle, P. F., Mathies, A. W., Leedom, J. M., Ivler, D. bacterial meningitis. *Ann. N. Y. Acad. Sci.* 145:488 – 498, 1967.
56. Weiss, C. F., Glazko, A. J., Westun, J. K., Chloramphenicol in the new born infant – A physiologic explanation of its toxicity when given in excess dose. *N. Eng. J. Med.* 262:787 – 794, 1960.
57. Westenfelder, G. O., Peterson, P. Y. Life – threatening infection: choice of alternate drugs when penicillin cannot be given. *J. A. M. A.* 210:845 – 848, 1969.

58. Yunis, A. A., Chloramphenicol – induced bone marrow suppression. *Semin. Hematol.* 10:225 – 234, 1973.(a)
59. Yunis A. A., Chloramphenicol toxicity: 25 years of research. *Am. J. Med.* 3 N:44N – 48N, 1989.(b)